Enrolling! Contact a study coordinator with questions

Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age

For more info: https://clinicaltrials.gov/study/NCT04649242

Primary Coordinator: Uyen Tran (Uyen@proc211.com)

Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age

For more info: https://clinicaltrials.gov/study/NCT04743141?id=C4951003&rank=1

Primary Coordinator: Uyen Tran (Uyen@proc211.com)

Phase 3 protocol to investigate the safety, tolerability, and immunogenicity of a BNT152b2 (LP.8.1) -- Adapted vaccine in children 5 through 11 years of age considered at high risk for severe COVID-19

For more info:

https://clinicaltrials.gov/study/NCT07222384

Primary Coordinator: Uyen Tran (Uyen@proc211.com)

Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to  Evaluate the Clinical Efficacy and Safety of Fucithalmic® (Fusidic Acid 1%) Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis

For more info: https://clinicaltrials.gov/study/NCT06911424

Primary Coordinator: Jack Wisman (Jack@proc211.com)

CorDx Tyfast Flu A/B & COVID-19/RSV Rapid Test in Anterior Nasal Samples for Over-the-Counter Use

For more info: https://clinicaltrials.gov/study/NCT04743141?id=C4951003&rank=1

Primary Coordinator: Jack Wisman (Jack@proc211.com)

Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12–15 Months of Age Concomitantly with Routine Pediatric Vaccines 

For more info:

https://clinicaltrials.gov/study/NCT06720038?locStr=Charlottesville,%20VA&country=United%20States&state=Virginia&city=Charlottesville&cond=pneumococcal%2031&rank=2&tab=table

Primary Coordinator: Cathy Hansa (Catherine@proc211.com)

Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12–15 Months of Age Concomitantly with Routine Pediatric Vaccines 

For more info:

https://clinicaltrials.gov/study/NCT06720038?locStr=Charlottesville,%20VA&country=United%20States&state=Virginia&city=Charlottesville&cond=pneumococcal%2031&rank=2&tab=table

Primary Coordinator: Cathy Hansa (Catherine@proc211.com)